|
1）Nishimura T, Nakatake Y, Konishi M, et al. Identification of a novel FGF, FGF-21, preferentially expressed in the liver. Biochim Biophys Acta. 2000; 1492: 203-6
|
|
|
|
2）Kharitonenkov A, Shiyanova TL, Koester A, et al. FGF-21 as a novel metabolic regulator. J Clin Invest. 2005; 115: 1627-35
|
|
|
|
|
3）Gaich G, Chien JY, Fu H, et al. The effects of LY2405319, an FGF21 analog, in obese human subjects with type 2 diabetes. Cell Metab. 2013; 18: 333-40
|
|
|
|
|
|
4）Hondares E, Iglesias R, Giralt A, et al. Thermogenic activation induces FGF21 expression and release in brown adipose tissue. J Biol Chem. 2011; 286: 12983-90
|
|
|
|
|
|
5）Adams AC, Yang C, Coskun T, et al. The breadth of FGF21?s metabolic actions are governed by FGFR1 in adipose tissue. Mol Metab. 2012; 2: 31-7
|
|
|
|
|
|
6）Emanuelli B, Vienberg SG, Smyth G, et al. Interplay between FGF21 and insulin action in the liver regulates metabolism. J Clin Invest. 2014; 124: 515-27
|
|
|
|
|
|
7）Lee P, Werner C, Kebebew E, et al. Functional thermogenic beige adipogenesis is inducible in human neck fat. Int J Obes. (Lond). 2014; 38: 170-6
|
|
|
|
|
|
8）Markan KR, Naber MC, Ameka MK, et al. Circulating FGF21 is liver derived and enhances glucose uptake during refeeding and overfeeding. Diabetes. 2014; 63: 4057-63
|
|
|
|
|
|
9）Owen BM, Ding X, Morgan DA, et al. FGF21 Acts Centrally to Induce Sympathetic Nerve Activity, Energy Expenditure, and Weight Loss. Cell Metab. 2014; 20: 670-7
|
|
|
|
|
|
10）Ornitz DM, Itoh N. Fibroblast growth factors. Genome Biol. 2001; 2: 1-12
|
|
|
|
|
|
11）Inagaki T, Choi M, Moschetta A, et al. Fibroblast growth factor 15 functions as an enterohepatic signal to regulate bile acid homeostasis. Cell Metab. 2005; 2: 217-25
|
|
|
|
|
|
12）Angelin B, Larsson TE, Rudling M. Circulating fibroblast growth factors as metabolic regulators-- a critical appraisal. Cell Metab. 2012; 16: 693-705
|
|
|
|
|
|
13）Suzuki M, Uehara Y, Motomura-Matsuzaka K, et al. βKlotho is required for fibroblast growth factor (FGF) 21 signaling through FGF receptor (FGFR) 1c and FGFR3c. Mol Endocrinol. 2008; 22: 1006-14
|
|
|
|
|
|
14）Kurosu H, Choi M, Ogawa Y, et al. Tissue-specific expression of betaKlotho and fibroblast growth factor (FGF) receptor isoforms determines metabolic activity of FGF19 and FGF21. J Biol Chem. 2007; 282: 26687-95
|
|
|
|
|
|
15）Inagaki T, Lin VY, Goetz R, et al. Inhibition of growth hormone signaling by the fasting-induced hormone FGF21. Cell Metab. 2008; 8: 77-83
|
|
|
|
|
|
16）Badman MK, Pissios P, Kennedy AR, et al. Hepatic fibroblast growth factor 21 is regulated by PPARalpha and is a key mediator of hepatic lipid metabolism in ketotic states. Cell Metab. 2007; 5: 426-37
|
|
|
|
|
|
17）Lundasen T, Hunt MC, Nilsson L-M, et al. PPARα is a key regulator of hepatic FGF21. Biochem Biophys Res Commun. 2007; 360: 437-40
|
|
|
|
|
|
18）Owen BM, Mangelsdorf DJ, Kliewer SA. Tissue-specific actions of the metabolic hormones FGF15/19 and FGF21. Trends Endocrinol Metab. 2015; 26: 22-9
|
|
|
|
|
|
19）Inagaki T, Dutchak P, Zhao G, et al. Endocrine regulation of the fasting response by PPARalpha-mediated induction of fibroblast growth factor 21. Cell Metab. 2007; 5: 415-25
|
|
|
|
|
|
20）Owen BM, Bookout AL, Ding X, et al. FGF21 contributes to neuroendocrine control of female reproduction. Nat Med. 2013; 19: 1153-6
|
|
|
|
|
|
21）Wei W, Dutchak PA, Wang X, et al. Fibroblast growth factor 21 promotes bone loss by potentiating the effects of peroxisome proliferator-activated receptor gamma. Proc Natl Acad Sci U S A. 2012; 109: 3143-8
|
|
|
|
|
|
22）Bookout AL, de Groot MH, Owen BM, et al. FGF21 regulates metabolism and circadian behavior by acting on the nervous system. Nat Med. 2013; 19: 1147-52
|
|
|
|
|
|
23）Zhang Y, Xie Y, Berglund ED, et al. The starvation hormone, fibroblast growth factor-21, extends lifespan in mice. Elife. 2012; 1: e00065
|
|
|
|
|
|
24）Veniant MM, Sivits G, Helmering J, et al. Pharmacologic effects of FGF21 are independent of the “Browning” of white adipose tissue. Cell Metab. 2015; 21: 731-8
|
|
|
|
|
|
25）Liu J, Xu Y, Hu Y, et al. The role of fibroblast growth factor 21 in the pathogenesis of non-alcoholic fatty liver disease and implications for therapy. Metabolism. 2015; 64: 380-90
|
|
|
|
|
|
26）Dushay J, Chui PC, Gopalakrishnan GS, et al. Increased fibroblast growth factor 21 in obesity and nonalcoholic fatty liver disease. Gastroenterology. 2010; 139: 456-63
|
|
|
|
|
|
27）Tanaka N, Takahashi S, Fang ZZ, et al. Role of white adipose lipolysis in the development of NASH induced by methionine- and choline-deficient diet. Biochim Biophys Acta. 2014; 1841: 1596-607
|
|
|
|
|
|
28）Fisher FM, Chui PC, Nasser IA, et al. Fibroblast growth factor 21 limits lipotoxicity by promoting hepatic fatty acid activation in mice on methionine and choline-deficient diets. Gastroenterology. 2014; 147: 1073-83. e6
|
|
|
|
|
|
29）Schaap FG, Kremer AE, Lamers WH, et al. Fibroblast growth factor 21 is induced by endoplasmic reticulum stress. Biochimie. 2013; 95: 692-9
|
|
|
|
|
|
30）Wan XS, Lu XH, Xiao YC, et al. ATF4- and CHOP-dependent induction of FGF21 through endoplasmic reticulum stress. Biomed Res Int. 2014; 2014: 807874
|
|
|
|
|
|
31）Jiang S, Yan C, Fang QC, et al. Fibroblast growth factor 21 is regulated by the IRE1alpha-XBP1 branch of the unfolded protein response and counteracts endoplasmic reticulum stress-induced hepatic steatosis. J Biol Chem. 2014; 289: 29751-65
|
|
|
|
|
|
32）Diaz-Delfin J, Hondares E, Iglesias R, et al. TNF-α represses β-Klotho expression and impairs FGF21 action in adipose cells: involvement of JNK1 in the FGF21 pathway. Endocrinology. 2012; 153: 4238-45
|
|
|
|
|
|
33）Kotulak T, Drapalova J, Kopecky P, et al. Increased circulating and epicardial adipose tissue mRNA expression of fibroblast growth factor-21 after cardiac surgery: possible role in postoperative inflammatory response and insulin resistance. Physiol Res. 2011; 60: 757-67
|
|
|
|
|
|
34）Hulejova H, Cerezo LA, Kuklova M, et al. Novel adipokine fibroblast growth factor 21 is increased in rheumatoid arthritis. Physiol Res. 2012; 61: 489-94
|
|
|
|
|